Regeneron Surges to $927.89, Clearing Its 52-Week High by 8.9%
As seen on the 24/7 Wall St. homepage on October 30, 2026.
Regeneron's Q3 earnings beat lifted it to a fresh 52-week high of $927.89, clearing the September 2 peak by 8.9%. That single jump erases months of range-bound trading in the biotech.
Continue ReadingShow less
Regeneron's Q3 earnings report beat expectations and pushed the stock to $927.89, a level it has not reached in the past year. That clears the previous 52-week peak, set on September 2, by 8.9%.
For much of the past several months the stock ground through a prolonged range, repeatedly failing to sustain gains above the $800 level before pulling back. A single earnings-driven session cut through that pattern.
Sponsored
This breakout sets a fresh annual high and erases months of sideways action. Buyers entering at all-time highs are not sitting on losses, which reduces the overhead selling pressure that can stall a rally.
The question for investors is whether the earnings beat was a one-quarter event or the start of a rerating. The September 2 peak had capped the stock for nearly two months, and the size of the gap above it suggests the Q3 results shifted how the market prices the company's outlook.
Sources
Mentioned: REGN